Actions

Test2: Difference between revisions

From haematologyetc.co.uk

No edit summary
Tag: Manual revert
No edit summary
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
<div style="background-color: #E0EEEE; {{round corners}} padding: 2em 2em;  margin-right: 5px;">




:CD3 is a reliable marker of T cell lineage that is primarily used to distinguish between T and B cells. The pattern of expression has diagnostic relevance.




<span style="color:navy>1. ''Markers used mainly for gating:''</span>
</div>
 
 
<span style="color:navy">'''Normal expression and function'''</span>
 
 
CD3 is a multi-molecular complex that associates with the T cell receptor of mature T cells, and supports TCR expression and intracellular signalling in response to antigen.  It is first expressed in the cytoplasm of pro-thymocytes before migrating to the T-cell surface during thymic maturation. CD3 expression is almost exclusive to mature T cells (there is weak expression of CD3 by some macrophages).
 
 
 
<span style="color:navy">'''Diagnostic role'''</span>  
 
 
* '''T-ALL''''' Expression is mainly cytoplasmic (cyCD3). Surface (sCD3) is usually absent in Early T-precursor T-ALL but is variably expressed in more mature T-ALL.
 
* '''Mature T cell neoplasms''': sCD3 is expressed on T cell lymphoproliferative disorders. The level of CD3 expression is increased (compared to normal T cells) in T-PLL and T-LGL, and is decreased in Sézary syndrome and ATLL
 
* '''Natural Killer cell lymphoproliferative disorders''': do not express a conventional TCR so CD3 is not expressed.
 
* '''Other''' B cells rarely express CD3, and aberrant expression in AML is rare (in contrast to other T cell markers such as CD2 or CD7).




{|style="width: 80px; height: 80px; text-align:center; font-style: bold; font-size: 120%; color: teal; background: #cccccc; border-style: solid; border-width: 2px"
|
[[CD45|<span style="color:teal">'''CD45'''</span>]]
|}
----
----
<span style="color:navy">'''''SUMMARY TABLES'''''</span>
Expression by acute leukaemias and by haematogones
<gallery widths="40px" heights="40px" >
File:rare.png|''Pro-B ALL''|link=Flow cytometry key
File:rare.png|''Early pre-B ALL''|link=Flow cytometry key
File:rare.png|''Pre-B ALL''|link=Flow cytometry key
File:rare.png|''B ALL''|link=Flow cytometry key
File:Hi.png|''Pro-T ALL''|link=Flow cytometry key
File:Hi.png|''Mature-T ALL''|link=Flow cytometry key
File:Poss.png|''AML'' *|link=Flow cytometry key
File:Rare.png|''Haemato-gones''|link=Flow cytometry key
</gallery>
<span style="font-size:80%">'''*''' May be seen in AML but consider bi-phenotypic if present</span>
Expression by B-lymphoproliferative disorders
<gallery widths="40px" heights="40px" >
File:rare.png|frame|''CLL''|link=Flow cytometry key
File:rare.png|''PLL''|link=Flow cytometry key
File:rare.png|''MCL''|link=Flow cytometry key
File:Poss.png|''FL'' *|link=Flow cytometry key
File:rare.png|''HCL''|link=Flow cytometry key
File:rare.png|''HCLv''|link=Flow cytometry key
File:rare.png|''MZL''|link=Flow cytometry key
File:rare.png|''LPL''|link=Flow cytometry key
File:rare.png|''PCs''|link=Flow cytometry key
</gallery>
<span style="font-size:80%">'''*''' occasionally described in FL</span>




Expression by mature T-cell disorders


<span style="color:navy>2. ''Non CD-classified markers''</span>
<gallery widths="40px" heights="40px" >
File:Hi.png|frame|''T-PLL''|link=Flow cytometry key
File:Hi.png|''T-LGL''|link=Flow cytometry key
File:Rare.png|''NK-LGL''|link=Flow cytometry key
File:Hi.png|''ATLL'' *|link=Flow cytometry key
File:Hi.png|''Sezary'' *|link=Flow cytometry key
File:Freq.png|''Others'' **|link=Flow cytometry key
</gallery>


<span style="font-size:80%">'''*''' expression may be dim</span>


{|style="float:left; width: 80px; height: 80px; text-align:center; font-style: bold; color: teal; border-style: solid; border-width: 2px; margin: 5px"
<span style="font-size:80%">'''**''' a range of other T cell disorders may circulate occasionally, marker expression varies</span>
|
'''[[Immunoglobulin light chains|<span style="color:teal">'''kappa'''</span>]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: navy; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[Immunoglobulin light chains|lambda]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: navy; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[FMC7]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: navy; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[TDT]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: italic; color: navy; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[MPO]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: navy; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[IgM]]'''
|}
----
----
'''KEY'''




<div class="toccolours mw-collapsible mw-collapsed" style="font-size 80%; overflow:auto;">


3. '''CD-classified markers frequently used in leukaemia diagnosis'''
The indicated expression frequency, indicates the approximate frequency of occurrence in each particular disease type.


{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD2]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD3]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color:  teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD5]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color:  teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD10]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color:  teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD11c]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color:  teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD13]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color:  teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD14]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color:teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD19]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color:  teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD22]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color:  teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD23]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color:  teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD25]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color:  teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD33]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD34]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color:  teal;; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD38]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color:  teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD79a]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color:  teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD79b]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color:  teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD103]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color:  teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD117]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color:  teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD138]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color:  teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD200]]'''
|}


[[File:Rare.png|30px|link=]]


----
rare (<5%)
 
[[File:Poss.png|30px|link=]]
 
possible (5-20%)
 
[[File:Mod.png|30px|link=]]
 
likely (20-40%)
 
[[File:Freq.png|30px|link=]]
 
frequent (40-80%)
 
[[File:Hi.png|30px|link=]]


expected (>80%)


4. '''Other markers helpful in diagnosis'''


{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: navy; border-style: solid; border-width: 15px; margin: 5px"
Where expression level is unusual or characteristic of a disorder this is indicated by text:
|
'''[[TCRαβ]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: navy; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[TCRγδ]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: navy; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[HLA-DR]]'''
|}


<BR clear=all>


{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: teal; border-style: solid; border-width: 15px; margin: 5px"
</div>
|
'''[[CD1a]]'''*
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD4]]'''*
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD7]]'''*
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD8]]'''*
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD11b]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD15]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD16]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD20]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD24]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD41]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD43]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD56]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD57]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD61]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD64]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD65]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD123]]'''
|}
{|style="float:left; width: 100px; height: 100px; text-align:center; font-style: bold; color: teal; border-style: solid; border-width: 15px; margin: 5px"
|
'''[[CD235]]'''
|}


----
----

Latest revision as of 13:17, 3 March 2023


CD3 is a reliable marker of T cell lineage that is primarily used to distinguish between T and B cells. The pattern of expression has diagnostic relevance.



Normal expression and function


CD3 is a multi-molecular complex that associates with the T cell receptor of mature T cells, and supports TCR expression and intracellular signalling in response to antigen. It is first expressed in the cytoplasm of pro-thymocytes before migrating to the T-cell surface during thymic maturation. CD3 expression is almost exclusive to mature T cells (there is weak expression of CD3 by some macrophages).


Diagnostic role


  • T-ALL Expression is mainly cytoplasmic (cyCD3). Surface (sCD3) is usually absent in Early T-precursor T-ALL but is variably expressed in more mature T-ALL.
  • Mature T cell neoplasms: sCD3 is expressed on T cell lymphoproliferative disorders. The level of CD3 expression is increased (compared to normal T cells) in T-PLL and T-LGL, and is decreased in Sézary syndrome and ATLL
  • Natural Killer cell lymphoproliferative disorders: do not express a conventional TCR so CD3 is not expressed.
  • Other B cells rarely express CD3, and aberrant expression in AML is rare (in contrast to other T cell markers such as CD2 or CD7).


SUMMARY TABLES


Expression by acute leukaemias and by haematogones

  • Rare.png

    Pro-B ALL

  • Rare.png

    Early pre-B ALL

  • Rare.png

    Pre-B ALL

  • Rare.png

    B ALL

  • Hi.png

    Pro-T ALL

  • Hi.png

    Mature-T ALL

  • Poss.png

    AML *

  • Rare.png

    Haemato-gones

* May be seen in AML but consider bi-phenotypic if present


Expression by B-lymphoproliferative disorders

  • Rare.png

    CLL

  • Rare.png

    PLL

  • Rare.png

    MCL

  • Poss.png

    FL *

  • Rare.png

    HCL

  • Rare.png

    HCLv

  • Rare.png

    MZL

  • Rare.png

    LPL

  • Rare.png

    PCs

* occasionally described in FL


Expression by mature T-cell disorders

  • Hi.png

    T-PLL

  • Hi.png

    T-LGL

  • Rare.png

    NK-LGL

  • Hi.png

    ATLL *

  • Hi.png

    Sezary *

  • Freq.png

    Others **

* expression may be dim

** a range of other T cell disorders may circulate occasionally, marker expression varies

KEY


The indicated expression frequency, indicates the approximate frequency of occurrence in each particular disease type.


File:Rare.png

rare (<5%)

File:Poss.png

possible (5-20%)

File:Mod.png

likely (20-40%)

File:Freq.png

frequent (40-80%)

File:Hi.png

expected (>80%)


Where expression level is unusual or characteristic of a disorder this is indicated by text:


Retrieved from ‘https://haematologyetc.co.uk/index.php?title=Test2&oldid=103’